Loading...
Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients
Doebele, R Perez, L Trinh, H Martinec, M Martina, R Riehl, T Krebs, Matthew G Meropol, N Wong, W Crane, G
Doebele, R
Perez, L
Trinh, H
Martinec, M
Martina, R
Riehl, T
Krebs, Matthew G
Meropol, N
Wong, W
Crane, G
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Doebele R, Perez L, Trinh H, Martinec M, Martina R, Riehl T, et al. P1.01-83 Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients. Journal of Thoracic Oncology. 2019;14(10):S392.